v3.26.1
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

11. Segment Reporting

The Company operates and reports its results in one reportable segment, on a consolidated basis. The Company reports segment information based on the management approach and organizes its business based on products and services. The management approach designates the internal reporting information regularly reviewed by the chief operating decision maker (the “CODM”) to make decisions about resources to be allocated to the segment and assess its performance as the basis for determining a company’s reportable segments. The Company’s CODM is the senior executive management team that includes the Chief Executive Officer and Chief Financial Officer. iMDx is an early-stage diagnostics technology company with core operations that include the research, development and commercialization of diagnostic tests. Currently, the Company’s revenues include Laboratory Services from its life sciences customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests, and to a lesser extent from Kitted Products (see Note 2, “Revenue Recognition” for additional information). Additionally, the Company is primarily focused on developing and commercializing new diagnostic tests for medical use related to organ transplant and in the field of oncology, accordingly, extensive resources, time and expense will be required to complete the development and commercialization of those tests.

Adjusted earnings or loss before interest, income taxes, depreciation and amortization is the singular measure of segment profit or loss that the CODM uses in assessing segment performance and deciding how to allocate resources. This measure of segment profit or loss is used to monitor budget versus actual results and for long range planning. Segment loss in the table below includes revenues, cost of revenues, research and development, and other significant operating expenses directly attributable to our reportable segment. Such operating expenses exclude depreciation and amortization expenses, stock-based compensation, the change in fair value of contingent consideration, and impairments. As an early-stage company with limited revenue, management believes this measure of profit or loss is helpful in assessing our ongoing performance, providing insight into the Company’s core operating costs and performance by excluding certain noncash and other non-operating items that may obscure the underlying trends in the business. The reconciling items and significant segment expense categories and amounts, as included in the table below, are based on the Company’s internal general ledger reporting system that is used in preparing our consolidated financial statements and are included in determining the measure of segment profit or loss that is used by the CODM.

The measure of segment assets is reported in the consolidated balance sheets as total assets. Total segment expenditures for additions to long-lived assets is reported in the consolidated statements of cash flows as a component of cash used in investing activities.

The Company's single reportable segment profit or loss information is as follows:

 

 

 

Years Ended
December 31,

 

 

 

2025

 

 

2024

 

 

 

(In thousands)

 

Laboratory Services

 

$

4,031

 

 

$

1,859

 

Laboratory Developed Test Services

 

 

—

 

 

 

22

 

Kitted Products

 

 

24

 

 

 

—

 

Total net revenues

 

 

4,055

 

 

 

1,881

 

Less:

 

 

 

 

 

 

Cost of revenues, as adjusted

 

 

1,668

 

 

 

983

 

Personnel-related expenses and board fees

 

 

12,823

 

 

 

11,000

 

Professional fees, legal, and outside services

 

 

7,974

 

 

 

5,008

 

Facilities and insurance

 

 

1,758

 

 

 

2,071

 

Laboratory supplies and expenses

 

 

3,930

 

 

 

1,826

 

Marketing and advertising

 

 

582

 

 

 

257

 

Travel and entertainment

 

 

849

 

 

 

585

 

Other segment items (1)

 

 

633

 

 

 

81

 

Segment loss

 

 

(26,162

)

 

 

(19,930

)

Reconciliation of segment profit and loss:

 

 

 

 

 

 

Depreciation and amortization expenses

 

 

(2,197

)

 

 

(1,564

)

Stock-based compensation

 

 

(2,219

)

 

 

(1,753

)

Change in fair value of contingent consideration

 

 

(5,946

)

 

 

4,275

 

Impairment losses

 

 

(14,600

)

 

 

(41,900

)

Impairment loss on held for sale assets

 

 

—

 

 

 

(169

)

Interest expense

 

 

(109

)

 

 

(84

)

Other income, net

 

 

1,011

 

 

 

462

 

Income taxes

 

 

—

 

 

 

—

 

Net loss

 

$

(50,222

)

 

$

(60,663

)

 

(1)
Other segment items primarily includes clinical trial expenses, delivery expenses, other business taxes and tax credits, and severance costs. For the years ended December 31, 2025 and 2024, clinical trial expenses were $301,000 and $2,000, respectively.

The Company's revenues and long-lived tangible assets by geographic area are presented below. Revenues are based on the customer country of domicile. Assets are based on the location of held assets.

 

 

 

Years Ended
December 31,

 

 

 

2025

 

 

2024

 

 

 

(In thousands)

 

Revenues by geographic area:

 

 

 

 

 

 

United States

 

$

4,031

 

 

$

1,673

 

Europe

 

 

24

 

 

 

18

 

United Kingdom

 

 

—

 

 

 

45

 

Asia-Pacific

 

 

—

 

 

 

145

 

Total net revenues

 

$

4,055

 

 

$

1,881

 

 

 

 

December 31,

 

 

 

2025

 

 

2024

 

 

 

(In thousands)

 

Long-lived tangible assets by geographic area:

 

 

 

 

 

 

United States

 

$

7,177

 

 

$

5,543

 

Europe

 

 

1,577

 

 

 

611

 

United Kingdom

 

 

433

 

 

 

—

 

Asia-Pacific

 

 

63

 

 

 

170

 

Total

 

$

9,250

 

 

$

6,324